- Liz Highleyman | 16 April 2018
Although people living with HIV may be diagnosed with cancer at an earlier stage because they get more consistent care than the general population, it is also possible that a ...
- Liz Highleyman | 04 April 2018
An 8-week course of grazoprevir/elbasvir (Zepatier) produced sustained virological response in most
HIV-positive gay men with recent hepatitis C virus (HCV) genotype 1 or 4
infection, according to a presentation at the ...
- Liz Highleyman | 27 March 2018
Use of an integrase inhibitor, which can bring
down viral load rapidly, was not associated with an increased risk of immune
reconstitution inflammatory syndrome (IRIS) in people who started
antiretroviral treatment with very ...
- Gus Cairns | 26 March 2018
South African researchers presenting a study at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2018) have suggested that the reason the extremely high rates of
HIV infection in women ...
- Liz Highleyman | 22 March 2018
People who switched from an antiretroviral
regimen containing abacavir to one containing tenofovir alafenamide (TAF)
showed less platelet reactivity, which reduces platelet aggregation or blood
clotting, according to a report at the 25th ...
- Liz Highleyman | 21 March 2018
People with HIV are more likely to develop cardiovascular conditions, including atherosclerosis and peripheral artery disease, than their HIV-negative counterparts, researchers reported at the 25th Conference on Retroviruses and Opportunistic ...
- Michael Carter | 20 March 2018
People with HIV aged 60 and over in the United States are more than twice as
likely to have an AIDS-defining illness or a CD4 cell count below 200 compared
to under-40s, ...
- Gus Cairns | 19 March 2018
A European study of men who have sex with men (MSM) presented
at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2018) shows that age makes a considerable
difference to whether ...
- Gus Cairns | 15 March 2018
The state of New South Wales in Australia has seen a fall of one-third in diagnoses of recent HIV infection since it started its pre-exposure prophylaxis (PrEP) implementation project, EPIC-NSW ...
- Liz Highleyman | 14 March 2018
More than half of people in low- and middle-income countries may not maintain viral suppression on second-line antiretroviral therapy (ART), according to a study presented at the 25th Conference on ...
- Carole Leach-Lemens | 14 March 2018
Lesotho, in spite of a high HIV prevalence of over 25%, is making substantial progress toward meeting the UNAIDS 90-90-90 targets, with a reported 77% of adults who tested positive ...
- Keith Alcorn | 13 March 2018
Very early HIV treatment in infants is feasible and safe and leads to a small reservoir of infected cells, two studies from Botswana and Thailand show. The findings offer hope ...
- Carole Leach-Lemens | 13 March 2018
Isoniazid preventive therapy (IPT) during and after pregnancy in women living with HIV on antiretroviral therapy (ART) in tuberculosis (TB) endemic areas in Africa, Asia and Haiti resulted in serious ...
- Michael Carter | 13 March 2018
Treatment with extended-release naltrexone is associated with improved viral suppression among HIV-positive prisoners, according to two US studies presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2018) ...
- Gus Cairns | 12 March 2018
MK-8591 or EFdA is a novel and exceptionally long-lasting and potent HIV drug, being developed by Merck. It is a nucleoside reverse transcriptase translocation inhibitor (NRTTI). Its potency and longevity ...
- Roger Pebody | 12 March 2018
HIV self-testing is feasible and acceptable for men who have sex with men (MSM) and transgender women (TGW), engaging more people than usual testing services, according to the results of ...
- Gus Cairns | 09 March 2018
A presentation at the recent 25th Conference on Retroviruses and Opportunistic Infections (CROI 2018) describes what
appears to be another case of infection with HIV in someone consistently taking pre-exposure prophylaxis ...
- Gus Cairns | 09 March 2018
A study presented at the recent 25th Conference on Retroviruses and Opportunistic Infections (CROI 2018) aims to
quantify how many people with HIV there might be in the community who both ...
- Liz Highleyman | 08 March 2018
Ibalizumab, a long-acting monoclonal antibody
that prevents HIV from entering cells, is active against virus strains that
have developed resistance to multiple other antiretrovirals, according to a
poster presentation at the 25th Conference ...
- Liz Highleyman | 08 March 2018
Both HIV-positive and HIV-negative people who use
statins to manage cardiovascular disease risk also have a lower risk of cancer,
according to research presented yesterday at the 25th
Conference on Retroviruses and Opportunistic ...
Antiretroviral drug chartA one-page reference guide to the anti-HIV drugs licensed for use in the UK or European Union, with information on formulation, dosing, key side effects and food requirements.
Your next stepsA booklet with information for people who’ve just found
out they have HIV.
Coming soon: news from IAS 2019 05 July 2019The 10th International AIDS Society
conference (IAS 2019) is being held...
Those who are not seen are not heard 01 July 2019A commentary on Optimising the Impact of Key Population Programming...
The fight for access to abortion care in Europe 27 June 2019Access to
sexual and reproductive health and rights includes safe and...